Combo of BO-112 and Pembrolizumab Elicits Response in Advanced Melanoma

Source: Targeted Oncology, April 2022

In patients with advanced melanoma who were resistant to anti–PD-1 therapies, adding BO-112 to pembrolizumab (Keytruda) demonstrated efficacy and safety, according to final results from the phase 2 SPOTLIGHT203 trial (NCT04570332).

At a median follow-up of 4.1 months (95% CI, 3.9-6.3), findings showed that among patients evaluable for response (n = 40), the combination of BO-112 and pembrolizumab achieved an overall response rate (ORR) of 25%, including a complete response rate of 10% and a partial response rate of 15%. Additionally, 40% had stable disease, and the disease control rate (DCR) was 65%.

“The responses happened in patients including [those with] BRAF-mutated and wild-type melanoma, mucosal histology, and secondary anti–PD-1 resistance. However, patients with acral melanoma or very high lactate dehydrogenase [LDH] have no clinical benefit,” lead study author Iván Márquez-Rodas, MD, PhD, of Hospital General Universitario Gregorio Marañón in Madrid, Spain, said in the presentation.